New brain scans may reveal why nerves die in MS
NCT ID NCT04532944
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used advanced MRI scans to look at energy use in the brains of 40 people with multiple sclerosis and 15 healthy volunteers. The goal was to see if energy problems in brain cells can predict nerve damage over two years. Researchers hope this will help understand how MS causes disability and lead to better treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify early signs of nerve damage in MS, guiding future treatments to protect the brain.
- What could go wrong
- This is an observational imaging study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all MS patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
59 people
The number who actually took part.
- Started
-
Jan 2021
- Finished
-
Jul 2025
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for MS: 1. RR-MS patients with a disease duration of less than 10 years: * 18-55 years * clinically defined RR-MS according to the 2017 revised McDonald's criteria (MS diagnostic criteria 2017) * disease duration \<10 years * ability to understand the research objectives and the procedure details, and to sign the informed consent * affiliation with the French National Health Insurance, Universal Medical Coverage (CMU) or any equivalent 2. Patients with progressive MS (primary or secondary) of less than 10 years: * 18-55 years * clinically defined progressive MS according to the 2017 revised McDonald's criteria * disease duration \<10 years from the beginning of the progressive phase * ability to understand the research objectives and the procedure details, and to sign the informed consent * affiliation with the French National Health Insurance, Universal Medical Coverage (CMU) or any equivalent Inclusion Criteria for healthy controls: * 18-55 years (matched with patients) * no known general pathologies * ability to understand the research objectives and the procedure details, and to sign the informed consent * affiliation with the French National Health Insurance, Universal Medical Coverage (CMU) or any equivalent Exclusion Criteria for MS: * Pregnant or breastfeeding women * Last infusion of cyclophosphamide, mitoxantrone or methylprednisolone realized less than 1 month before inclusion * last clinical relapse less than one month before inclusion * severe cardiac, pulmonary, hepatic, hematologic renal, gastrointestinal disease, or cancer * contraindications to MRI: claustrophobia, pace-maker implant, any surgical ferromagnetic clips, ocular implants, any intraocular or intracranial metallic fragments, any metallic objects able to concentrate the radiofrequency field, cochlear implants, cardiac or brain stimulators, any tattoos or permanent makeup on the face, renal failure (exclusion criterion for gadolinium injection) patients not willing to be informed of any possible cerebral malformations incidentally discovered at the MRI exam * severe renal failure (clearance of creatinine \< 30ml/min) * history of allergic reactions to gadolinium salts * any other chronic neurological disorders associated * persons deprived of liberty by law or by administrative decision * Persons under legal protection Exclusion Criteria for healthy controls: * Pregnant or breastfeeding women * severe cardiac, pulmonary, hepatic, hematologic renal, gastrointestinal disease, or cancer * contraindications to MRI : claustrophobia, pace-maker implant, any surgical magnetic clips, ocular implants, any intraocular or intracranial metallic fragments, any metallic objects able to concentrate the radiofrequency field, cochlear implants, cardiac or brain stimulators, any tattoos or permanent makeup on the face * person not willing to be informed of any possible cerebral malformations incidentally discovered at the MRI exam * associated chronic neurological disorders * persons deprived of liberty by law or by administrative decision * Persons under legal protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICM, Hôpital Pitié Salpêtrière, 47 Boulevard de l'Hôpital
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Under-the-Skin MS drug: can a shot replace an IV drip?
- Can a common antihistamine boost multiple sclerosis treatment?
- Can exercise rebuild muscle and balance in MS?
- Can diet ease the crushing fatigue of multiple sclerosis?
- One-Time CAR-T infusion tested against progressive MS
- Can PET scans reveal hidden brain inflammation in MS?